SecBot SecBot
Biotech Drug Report Generated Oct 28, 2026

QALSODY

BIIB·BIOGEN INC.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved (accelerated approval)
Time to market
Already approved and commercially available in the US (since April 2023) and EU (since May 2024), plus 42 other countries.
Why 3/10
QALSODY is already FDA-approved (accelerated approval, April 2023) and commercially launched. The next hard catalyst is the ATLAS Phase 3 confirmatory trial readout, but its estimated primary completion is August 2027, more than 12 months away. No PDUFA or pivotal readout is scheduled in the next year. QALSODY is a small part of Biogen's large, diversified pipeline (~$10B total revenue), so even a major QALSODY-specific event would not be a make-or-break binary for the stock.
Actionable Insight NEUTRAL

The next hard catalyst for QALSODY is the ATLAS Phase 3 confirmatory trial readout, but its estimated primary completion is August 2027, more than 12 months away. With no imminent PDUFA or pivotal readout, QALSODY is unlikely to drive a major standalone move in BIIB shares in the near term. Watch for quarterly sales growth trajectory and any updates on the ATLAS enrollment or potential interim analysis.

Price Chart

Loading chart...

Executive Summary

QALSODY (tofersen) is an FDA-approved antisense oligonucleotide therapy from Biogen (BIIB) that targets the genetic cause of SOD1-ALS, an ultra-rare neurodegenerative disease affecting roughly 2% of ALS patients. It received accelerated FDA approval in April 2023 based on biomarker data (reduction in neurofilament light chain), followed by European approval in May 2024. The drug is now approved in 44 countries and generated approximately $33M in global revenue in Q1 2026. While long-term data published in JAMA Neurology (December 2025) showed that early treatment slows functional decline, the drug's commercial impact on Biogen is modest given the tiny patient population. The key upcoming catalyst is the ATLAS Phase 3 confirmatory trial in presymptomatic SOD1 carriers, but its estimated primary completion is August 2027, leaving no imminent binary event for this drug.

How It Works

QALSODY is an antisense oligonucleotide (a short, lab-made piece of genetic material) designed to bind to the messenger RNA that carries instructions for making the SOD1 protein. By binding to this RNA, it reduces production of the SOD1 protein, which in its mutated form is toxic to nerve cells and causes ALS. The drug is administered via lumbar puncture (intrathecal injection into the spinal fluid) every few weeks.

Trial Status

QALSODY is FDA-approved under accelerated approval based on the Phase 3 VALOR trial and its open-label extension. The confirmatory Phase 3 ATLAS trial (NCT04856982) in presymptomatic SOD1 mutation carriers is active but not recruiting, with an estimated primary completion date of August 2027 and final completion in April 2028. A Phase 2 trial in non-SOD1 ALS began enrollment in December 2025. Long-term VALOR OLE results were published in JAMA Neurology in December 2025, showing that early treatment with tofersen slows functional decline and reduces neurofilament light levels over 2+ years.

The Two-Sided Case

▲ Bull Case4
QALSODY is the first and only approved treatment targeting a genetic cause of ALS, a major scientific breakthrough. Long-term data published in JAMA Neurology (December 2025) showed early treatment with tofersen slows functional decline and reduces neurofilament light (NfL) over 2+ years, with some patients experiencing symptom reversal.
The drug has received approval in 44 countries, including the US (accelerated approval April 2023) and EU (May 2024), with expanding global reimbursement. Biogen's 2025 annual report noted QALSODY revenue 'grew notably' in 2025, driven by strong demand.
The ongoing ATLAS trial is the first-ever interventional study in presymptomatic SOD1 mutation carriers. If positive, it could expand the treatable population and potentially support conversion from accelerated to full FDA approval.
A Phase 2 trial in non-SOD1 ALS began in December 2025, which if successful could dramatically expand the addressable market beyond the current ultra-rare SOD1 population.
▼ Bear Case4
QALSODY received only accelerated FDA approval based on a biomarker (NfL reduction), not on definitive clinical endpoints. The VALOR Phase 3 trial missed its primary endpoint (change in ALSFRS-R at 28 weeks), and continued approval depends on the ATLAS confirmatory trial, which is not expected to complete until 2028.
The addressable patient population is ultra-rare: roughly 2% of ALS cases carry an SOD1 mutation, or fewer than 5,000 patients globally. This caps peak sales potential; Q1 2026 global revenue was only $33M, a tiny fraction of Biogen's ~$10B annual revenue.
QALSODY is priced at ~$130,000/year and requires intrathecal administration (spinal injections), which limits patient access and requires specialized infusion centers.
The drug faces potential competition from other SOD1-targeting therapies in development, including gene-editing and other ASO approaches.

Upcoming Catalysts

  • ATLAS Phase 3 confirmatory trial primary completion (estimated August 2027) - could support conversion from accelerated to full FDA approval
  • Phase 2 trial in non-SOD1 ALS (started December 2025) - if positive, could dramatically expand addressable market
  • Quarterly sales growth trajectory as global reimbursement expands across 44 approved countries

Source Filing

The SecBot filing or press-release report that triggered this drug report:

BIOGEN INC. 8-K BIIB ·Originating report

Sources · 11

Hover a chip for the title
1 investors.biogen.com2 investors.biogen.com3 investors.biogen.com4 clinicaltrials.gov5 fda.gov6 ninds.nih.gov7 ainvest.com8 ir.ionis.com9 investors.biogen.com10 accessdata.fda.gov11 sec.gov